Stockscreener 앱 받기
0.00
100.00%
-17.16
전일 마감가:
$17.16
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$59.90M
수익:
$9.16M
순이익/손실:
$-68.17M
주가수익비율:
0.00
EPS:
-1.63
순현금흐름:
$-80.16M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$23.28
아이케나 온콜로지 Stock (IKNA) Company Profile
명칭
Ikena Oncology Inc
전화
857-343-8292
주소
50 NORTHERN AVE., BOSTON
IKNA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IKNA
Ikena Oncology Inc
|
0.00 | 59.90M | 9.16M | -68.17M | -80.16M | -1.63 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
아이케나 온콜로지 Stock (IKNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-29 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-09-22 | 개시 | Wedbush | Outperform |
| 2023-05-04 | 재개 | H.C. Wainwright | Buy |
| 2021-12-23 | 개시 | H.C. Wainwright | Buy |
| 2021-05-05 | 재개 | Credit Suisse | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-04-20 | 개시 | Credit Suisse | Outperform |
| 2021-04-20 | 개시 | Jefferies | Buy |
| 2021-04-20 | 개시 | William Blair | Outperform |
모두보기
아이케나 온콜로지 주식(IKNA)의 최신 뉴스
Energy Moves: How Ikena Oncology Inc. stock reacts to Fed rate cutsJuly 2025 Momentum & Weekly Watchlist for Consistent Profits - BỘ NỘI VỤ
ImageneBio (NASDAQ:IMA) Lowered to “Underperform” Rating by Wedbush - Defense World
ImageneBio (NASDAQ:IMA) Rating Lowered to Underperform at Wedbush - Defense World
ImageneBio (NASDAQ:IMA) Downgraded to Underperform Rating by Wedbush - Defense World
ImageneBio (NASDAQ:IMA) Stock Rating Lowered by Wedbush - Defense World
How Ikena Oncology Inc. stock performs in interest rate cyclesWeekly Gains Report & Real-Time Market Sentiment Alerts - newser.com
Is Ikena Oncology Inc. stock attractive for ETFsJuly 2025 Breakouts & Weekly High Potential Stock Alerts - newser.com
Will Ikena Oncology Inc. stock sustain high P E ratios2025 Buyback Activity & Fast Gain Swing Alerts - newser.com
How Ikena Oncology Inc. stock trades during market volatilityStock Surge & Scalable Portfolio Growth Ideas - newser.com
What valuation multiples suggest for Ikena Oncology Inc. stockTrend Reversal & Safe Capital Growth Trade Ideas - newser.com
A activity2025 Historical Comparison & AI Powered Buy and Sell Recommendations - newser.com
FY2025 EPS Estimates for ImageneBio Cut by Leerink Partnrs - Defense World
William Blair Estimates ImageneBio FY2025 Earnings - Defense World
Is Ikena Oncology Inc. stock gaining market shareJuly 2025 Summary & Real-Time Market Sentiment Reports - newser.com
Analyzing recovery setups for Ikena Oncology Inc. investorsSell Signal & Reliable Price Action Trade Plans - newser.com
Applying big data sentiment scoring on Ikena Oncology Inc.Quarterly Profit Summary & Real-Time Buy Zone Alerts - newser.com
Using fundamentals and technicals on Ikena Oncology Inc.Global Markets & High Accuracy Buy Signal Tips - newser.com
Understanding Ikena Oncology Inc.’s price movementOptions Play & Daily Profit Focused Stock Screening - newser.com
ImageneBio (NASDAQ:IMA) Downgraded by Wall Street Zen to “Strong Sell” - Defense World
Published on: 2025-11-14 18:20:12 - newser.com
What Fibonacci levels say about Ikena Oncology Inc. rebound2025 Investor Takeaways & AI Powered Market Entry Ideas - newser.com
Is Ikena Oncology Inc. stock a buy on dipsQuarterly Market Summary & AI Enhanced Trading Alerts - Fundação Cultural do Pará
Will Ikena Oncology Inc. stock attract more institutional investors2025 Year in Review & Daily Stock Trend Reports - newser.com
[S-8] ImageneBio, Inc. Employee Benefit Plan Registration | IMA SEC FilingForm S-8 - Stock Titan
ImageneBio Reports Third Quarter 2025 Financial Results - TradingView
ImageneBio, Inc. SEC 10-Q Report - TradingView
[10-Q] ImageneBio, Inc. Quarterly Earnings Report | IMA SEC FilingForm 10-Q - Stock Titan
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team - The Manila Times
ImageneBio (Nasdaq: IMA) to amend Phase 2b ADAPTIVE trial; topline data expected 2027 - Stock Titan
How to recover losses in Ikena Oncology Inc. stockTrade Entry Report & Verified Entry Point Signals - newser.com
아이케나 온콜로지 (IKNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.44%
0.91%
자본화:
|
볼륨(24시간):